News

A study is recruiting participants to examine the molecular changes that occur when precursor conditions develop into full-blown multiple myeloma, information that can then be…

Janssen Pharmaceutical has submitted an application to Japanese authorities requesting that Darzalex (daratumumab) be approved, in combination with standard therapy, to treat newly diagnosed multiple myeloma patients…

The European Commission has approved a new dosing regimen of the treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive…

Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to…

Early treatment with a triple combination therapy containing Empliciti (elotuzumab), Revlimid (lenalidomide), and dexamethasone in patients with smoldering multiple myeloma — a precursor of…

The Multiple Myeloma Research Foundation (MMRF) is launching a platform clinical trial aimed at investigating treatments for high-risk multiple myeloma patients. Building on the…

An international Phase 2 trial testing the investigational CAR T-cell therapy bb2121 for the treatment of relapsed or refractory multiple myeloma patients has completed patient recruitment, …

Results from the first in-human clinical trial assessing Amgen’s immunotherapy AMG 420 showed promising results in multiple myeloma patients who had received at least…

Researchers have identified three genetic alterations associated with the known twofold to threefold risk of multiple myeloma among African-Americans. The study, “Differences…

Seattle Genetics is recruiting patients with relapsed or refractory multiple myeloma into a Phase 1 clinical trial to study the safety and tolerability of…